InflaRx N.V. (IFRX) reports that it has treated its first patient in a phase IIa clinical trial evaluating the Company’s lead product candidate, IFX-1 in Pyoderma Gangraenosum (PG). A rare and debilitating neutrophilic-driven autoinflammatory disease, characterized by...